多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果

Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis

目的研究多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者效果。方法选取2016年1月-2018年1月我院就诊的胃癌腹膜转移患者60例,随机分为对照组和观察组,每组30例。对照组给予多西他赛腹腔灌注加静脉化疗辅以口服替吉奥胶囊,观察组在对照组基础上加用阿帕替尼治疗,比较两组临床疗效、CEA、CA125、CA19-9、不良反应发生率及生存率。结果观察组总有效率为93.33%,高于对照组的66.67%(P<0.05);两组治疗后CEA、CA125、CA19-9水平低于治疗前,且观察组低于对照组(P<0.05);观察组不良反应总发生率及1、2、3年生存率高于对照组,但差异无统计学意义(P>0.05)。结论采用多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果理想,能有效降低肿瘤标志物水平,延长生存期,安全性较好。

Objective To study the effect of intraperitoneal perfusion of docetaxel plus intravenous chemotherapy and oral administration of tegafur combined with apatinib in the treatment of gastric cancer patients with peritoneal metastasis.Methods From January 2016 to January 2018,60 patients with peritoneal metastasis of gastric cancer in our hospital were randomly divided into control group and observation group,with 30 cases in each group.The control group was treated with docetaxel intraperitoneal perfusion plus intravenous chemotherapy combined with oral tegafur capsule.The observation group was treated with apatinib on the basis of the control group.The clinical efficacy,CEA,CA125,CA19-9,incidence of adverse reactions and survival rate were compared between the two groups.Results The total effective rate of the observation group was 93.33%,which was higher than 66.67%of the control group(P<0.05).After treatment,the levels of CEA,CA125 and CA19-9 in the two groups were lower than those before treatment,and those in the observation group were lower than the control group(P<0.05).The total incidence of adverse reactions and The 1-,2-and 3-year survival ratesin the observation group was higher than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Docetaxel intraperitoneal infusion combined with intravenous chemotherapy and oral tegafur combined with apatinib are effective in the treatment of gastric cancer with peritoneal metastasis,which can effectively reduce the level of tumor markers,prolong the survival time and have good safety.